Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fosun Pharma Holds 20 Percent Shares In Tongjitang Chinese Medicines

This article was originally published in PharmAsia News

Executive Summary

As of June 19, Fosun has purchased a total of 6.765 million American Depository Shares in Tongjitang Chinese Medicines, making it the owner of 20.02 percent ordinary shares issued by the latter. Industry analysts have been speculating that Fosun wanted to force Tongjitang to delist from the U.S. market and consolidate its TCM assets. However, others believe the firm is unlikely to do that due to the substantial amount of time and money needed. Fosun has little revenue contribution from its TCM business although its profit margins from the sector can be as high as 70.4 percent, which explains its interest in Tonjitang. Fosun consistently adheres to its claim that the purchase is simply for investment purposes. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel